share_log

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target

HC Wainwright & Co.重申买入加的夫肿瘤学,维持14美元的目标股价
Benzinga ·  05/06 06:27

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 price target.

HC Wainwright & Co. 分析师拉古拉姆·塞尔瓦拉朱重申加的夫肿瘤学(纳斯达克股票代码:CRDF)的买入并维持14美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发